Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09), Zacks reports. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ:ENTA traded down $0.33 during midday trading on Monday, hitting $10.66. 106,587 shares of the company’s stock were exchanged, compared to its average volume of 214,516. The stock has a 50 day moving average price of $11.95 and a 200-day moving average price of $13.08. The company has a market cap of $310.53 million, a PE ratio of -4.42 and a beta of 0.75. Enanta Pharmaceuticals has a 12 month low of $10.05 and a 12 month high of $17.15.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ENTA shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Thursday, October 15th. Finally, Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, October 11th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.00.

Get Our Latest Stock Analysis on ENTA

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.

Read More

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.